CYP450スーパーファミリーの自然ポリモルフィック変種:潜在的な構造的メカニズムと機能的結果のレビュー
Rafał Prost1, Wojciech Płaziński2,3
1Independent Researcher, 20-075 Lublin, Poland.
International journal of molecular sciences
|August 28, 2025
まとめ
このレビューでは,シトクロームP450 (CYP450) 酵素の遺伝的変異が薬の代謝と患者の反応にどのように影響するか詳細に説明します. これらのポリモルフィズムが酵素機能を変化させ,異種生物の代謝に影響を与える多様なメカニズムを強調しています.
科学分野:
- ファルマゲノミクス
- 酵素学
- 薬物の代謝
背景:
- サイトクロームP450 (CYP450) 酵素は,第I相薬代謝に不可欠です.
- CYP450遺伝子のポリモルフィズムにより,薬剤の有効性と安全性が著しく変化する可能性があります.
- パーソナライズされた医療には これらの変化を 総合的に理解することが不可欠です
研究 の 目的:
- 15の主要なCYP450酵素とその自然に存在する多形変異をレビューする.
- これらのポリモルフィズムが酵素機能と異種生物の代謝に与える影響を分析する.
- CYP450ポリモルフィズムの機能的結果の基礎となる分子機構を探求する.
主な方法:
- ユニプロットと科学文献から 多形変異のデータセットをまとめました
- 変異効果に関する in vitro,in vivo,および臨床試験データをレビューした.
- ポリモルフィズムメカニズムを理解するために,CYP450酵素の質的構造分析を行った.
主要な成果:
- 15のCYP450酵素に多数の多形変異が特定され,CYP3A4が最も臨床的に有意である.
- ポリモルフィズムが変化した膜指向,基板結合,およびリドックスパートナー相互作用を含む様々なメカニズムを通じて酵素機能に影響することを実証した.
- 機能的に有意なポリモルフィズムの中でアルギニン置換変異の過剰表現が観察されました.
結論:
- このレビューは,CYP450ポリモルフィズムとその重要性を体系的にまとめています.
- CYP450ポリモルフィズム効果は機械的に多様で,単一の普遍的なパターンに従っていません.
- これらの変化を理解することは 薬の反応を予測し管理する上で 鍵となるものです
関連する概念動画
01:17Drug Metabolism: Phase I Reactions
3.6K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.6K
00:49Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
01:19Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
01:14Drug Metabolism: Phase II Reactions
4.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.1K
01:19Factors Affecting Drug Biotransformation: Biological
231
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
231
01:16Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K